– USA, NC – Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that David W. Gryska has been appointed to the Company’s Board of Directors and will also be a member of the Audit Committee of the Board. David brings extensive executive level healthcare-focused and financial leadership experience from large global biopharmaceutical firms.
Mr. Gryska recently announced his planned retirement at the end of 2018 as the Chief Financial Officer and Executive Vice President of Incyte Corp., and is currently on the boards of Seattle Genetics, Inc. and PDL BioPharma, Inc. Previously, he held the position of President, CEO, COO and Director at Myrexis, Inc., Chief Financial Officer and Senior Vice President at Celgene Corp., and Chief Financial Officer and Senior Vice President at Scios, Inc. Mr. Gryska has spent over 20 years as a senior executive at life science and biotechnology companies with extensive experience relating to financings, acquisitions, global expansion and strategic transactions. Mr. Gryska was previously a member of Aerie’s Board of Directors from May of 2012 through May of 2015.
“We are pleased to welcome Dave back to the Company’s Board. He brings a tremendous amount of experience and strategic vision as Aerie moves forward into our most exciting period, from our successful Rhopressa launch, potential Roclatan regulatory approval, our global expansion and pursuit of new opportunities in our pipeline, including for retina diseases. He will be a highly valued contributor as we continue to build a major ophthalmic pharmaceutical company,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye. Aerie’s first product, Rhopressa 0.02%, a once-daily eyedrop approved by the U.S. Food and Drug Administration for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, cornea verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa, including the full product label, Aerie’s advanced-stage product candidate, Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a fixed-dose combination of Rhopressa and the widely-prescribed PGA (prostaglandin analog) latanoprost, achieved its 3-month primary efficacy endpoint in two Phase 3 registration trials, Mercury 1 and Mercury 2, and also showed safety and efficacy throughout 12 months in Mercury 1. Aerie submitted the Roclatan New Drug Application (NDA) in May 2018 and, in July 2018, the FDA set the PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA’s review of the Roclatan NDA for March 14, 2019. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
For more information : http://www.aeriepharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.